BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm. Blood-based Nodify Lung testing, comprised of the Nodify CDT® and N
Click here to view original post
News
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third […]
News
Broomfield remote patient monitoring startup snags $18M
The company’s device received initial clearance from the FDA in April. Click here to view original post
News
What, exactly, the new $400M offshoot of DaVita and Medtronic aims to do
Both companies contributed $200 million in capital to create Mozarc Medical, a new kidney health tech company. Click here to view original post
